|
|
| Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial |
| Jason Efstathiou, MD, DPhil |
| E David Crawford interviews Jason Efstathiou about the PARTIQoL trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou presents the study's design, methodology, and key findings. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights from the 2024 American Society For Radiation Oncology Annual Meeting |
|
|
|
|
| Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer
|
| Jason Efstathiou, MD, DPhil |
| The Phase III PARTIQoL trial, presented by Dr. Jason Efstathiou at ASTRO 2024, compared proton therapy (PBT) and intensity-modulated radiation therapy (IMRT) for localized prostate cancer. The study found no significant differences in health-related quality of life (HRQoL) outcomes, including bowel, urinary, and sexual functions, or cancer control between the two modalities at 24 months. Both treatments provided excellent HRQoL and tumor control, with no meaningful variation in progression-free survival or biochemical failure-free survival at five years.
|
|
|
|
|
|
| SBRT for Unfavorable Intermediate-Risk Prostate Cancer
|
| Daniel Spratt, MD
|
| Daniel Spratt provided an in-depth analysis of stereotactic body radiation therapy (SBRT) for unfavorable intermediate-risk prostate cancer (UIR-PCa). His presentation highlighted how the classification of intermediate-risk prostate cancer into favorable and unfavorable categories, first proposed in 2013, has helped refine prognosis and treatment strategies.
|
|
|
|
|
|
| Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer |
| Neil Desai, MD |
| Neil Desai discusses the role of ADT and genomic risk stratification for patients with unfavorable intermediate-risk prostate cancer. While ADT with radiation therapy reduces PSA failure and metastasis rates, decision-making remains complex due to limited reliable predictors of metastasis and various treatment options. Genomic classifiers like Decipher, Prolaris, and multi-modal AI models are showing promise in personalizing treatment by assessing the risk of metastasis and guiding the use of ADT, though their application is still evolving in clinical practice. |
|
|
|
|
|
| Role of Brachytherapy for Unfavorable Intermediate Risk Prostate Cancer
|
| Cynthia Menard, MD
|
| Cynthia Menard presents on the role of brachytherapy in treating patients with unfavorable intermediate-risk prostate cancer. The presentation highlighted several key studies and trials that emphasize the importance of dose escalation in this population, particularly in improving biochemical progression-free survival (bPFS) and metastasis-free survival (MFS).
|
|
|
|
|
|
|
|
|
|
|
| Long-Term Patient-reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial
|
| Karen Hoffman, MD, MHSc, MPH, FASTRO
|
| Karen Hoffman presents the long-term HRQoL outcomes from the FORMULA-509 trial. The trial compared the addition of abiraterone acetate/prednisone and apalutamide to salvage radiotherapy plus 6 months of ADT against bicalutamide in patients with unfavorable risk features post-radical prostatectomy.
|
|
|
|
|
|
| Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer |
| Noelia Sanmamed Salgado, MD, PhD |
| Noelia Sanmamed presented quality-of-life outcomes from a randomized trial comparing moderate hypofractionated radiotherapy to conventional fractionation for intermediate-risk prostate cancer. The study found no significant differences in patient-reported outcomes across most domains, including urinary, sexual, and hormonal function, between the two arms. |
|
|
|
|
|
| Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials |
| Martin King, MD, PhD |
| Martin King presented long-term results from the 44/20/0 trials evaluating supplemental external beam radiotherapy (EBRT) with Pd-103 implants in high-risk prostate cancer. The trials found no significant differences in biochemical failure or prostate cancer-specific mortality between varying EBRT doses. Higher biologic equivalent doses (BED) did not improve outcomes, even in unfavorable intermediate-risk patients. |
|
|
|
|
|
| A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High-risk Prostate Cancer: Efficacy Results at Median 6 Years |
| Juanita Crook, MD, FRCPC |
| Juanita Crook presents the long-term efficacy results from a randomized phase III trial comparing low-dose rate (LDR) and high-dose rate (HDR) brachytherapy boosts combined with external beam radiotherapy for unfavorable intermediate- or high-risk prostate cancer. At 6 years, no significant differences were observed between the LDR and HDR arms for biochemical progression-free survival or PSA ≤0.2 ng/ml at 4 years. Both arms demonstrated excellent biochemical cure rates at 8 years. |
|
|
|
|
|
| Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses |
| Colin Belliveau, MD |
| Colin Belliveau presented the results of a randomized controlled trial examining PSMA PET-guided intensification of salvage radiotherapy after radical prostatectomy for patients experiencing biochemical failure (PSA ≥0.1 ng/ml). The study aimed to determine if PSMA PET-guided treatment improves failure-free survival. |
|
|
|
|
|
| Natural History after Likely Cure versus Recurrence after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials |
| Soumyajit Roy, MS, MBBS
|
| The RAPTOR pooled analysis of over 13,000 patients across 21 randomized controlled trials examined outcomes in prostate cancer patients treated with radiation therapy. Patients with biochemical recurrence within 5 years had significantly higher rates of distant metastasis and prostate cancer-specific mortality compared to those without BCR. |
|
|
|
|
|
